The private versus public contribution to the biomedical literature during the COVID-19, Ebola, H1N1, and Zika public health emergencies.

ABSTRACT:

Background

The private versus public contribution to developing new health knowledge and interventions is deeply contentious. Proponents of commercial innovation highlight its role in late-stage clinical trials, regulatory approval, and widespread distribution. Proponents of public innovation point out the role of public institutions in forming the foundational knowledge undergirding downstream innovation. The rapidly evolving COVID-19 situation has brought with it uniquely proactive public involvement to characterize, treat, and prevent this novel health treat. How has this affected the share of research by industry and public institutions, particularly compared to the experience of previous pandemics, Ebola, H1N1 and Zika?

Methods

Using Embase, we categorized all publicati

SUBMITTER: Beall RF 

PROVIDER: S-EPMC8535173 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature